NCT02759588 2023-01-05GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerGenelux CorporationPhase 1/2 Completed46 enrolled
NCT00887536 2022-04-20A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerNSABP Foundation IncPhase 3 Completed1,613 enrolled
NCT00719264 2017-03-20Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerNovartisPhase 2 Completed365 enrolled 14 charts
NCT00737243 2016-08-17Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary SiteSCRI Development Innovations, LLCPhase 2 Completed289 enrolled 5 charts
NCT00666692 2012-04-27A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)AbbottPhase 1 Completed7 enrolled